The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
| Status: | Recruiting | 
|---|---|
| Conditions: | Lymphoma, Lymphoma | 
| Therapuetic Areas: | Oncology | 
| Healthy: | No | 
| Age Range: | 18 - Any | 
| Updated: | 6/16/2018 | 
| Start Date: | July 2015 | 
| End Date: | June 2020 | 
| Contact: | Julianne Lunde | 
| Email: | lunde.julianne@mayo.edu | 
| Phone: | 507-266-2657 | 
The goal of this infrastructure grant is to establish and maintain a cohort of over 12,000
non-Hodgkin lymphoma (NHL) patients to support broad and cutting-edge research that
identifies clinical (including co-morbid diseases), epidemiologic (including lifestyle and
other exposures), host genetic, tumor, and treatment factors, as well as the interaction
among these factors, on short and long-term outcomes. These efforts will identify new
approaches to improve the survival and well-being of NHL patients.
			non-Hodgkin lymphoma (NHL) patients to support broad and cutting-edge research that
identifies clinical (including co-morbid diseases), epidemiologic (including lifestyle and
other exposures), host genetic, tumor, and treatment factors, as well as the interaction
among these factors, on short and long-term outcomes. These efforts will identify new
approaches to improve the survival and well-being of NHL patients.
Newly diagnosed non-Hodgkin lymphoma (NHL) patients will be recruited from each center
participating in the LEO cohort. At time of consent, participants will be asked to completed
several questionnaires collecting health history, current medical and quality of life
questions. Patients will also provide a baseline blood sample that will processed locally and
stored centrally for future research use. Additionally, consent is given for use of excess
clinical tumor tissue for research use.
participating in the LEO cohort. At time of consent, participants will be asked to completed
several questionnaires collecting health history, current medical and quality of life
questions. Patients will also provide a baseline blood sample that will processed locally and
stored centrally for future research use. Additionally, consent is given for use of excess
clinical tumor tissue for research use.
Inclusion Criteria:
- Newly diagnosed non-Hodgkin Lymphoma (NHL), within 183 days of enrollment
- Patients may have been treated as long as initial NHL diagnosis is within 6 months of
enrollment
- 18 years of age or older
Exclusion Criteria:
- Lymphoma diagnosis greater than 184 days from date of consent
We found this trial at
    8
    sites
	
									201 Dowman Dr
Atlanta, Georgia 30303
	
			Atlanta, Georgia 30303
(404) 727-6123
							
					Principal Investigator: Christopher Flowers, MD
			
						
										Phone: 404-778-3942
					
		Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...  
  
  Click here to add this to my saved trials
	
									101 Jessup Hall
Iowa City, Iowa 52242
	
			Iowa City, Iowa 52242
(319) 335-3500 
							
					Principal Investigator: Brian Link, MD
			
						
										Phone: 319-467-5839
					
		University of Iowa With just over 30,000 students, the University of Iowa is one of...  
  
  Click here to add this to my saved trials
	
								Miami, Florida 33124			
	
			(305) 284-2211
							
					Principal Investigator: Izidore Lossos, MD
			
						
										Phone: 305-243-2712
					
		University of Miami A private research university with more than 15,000 students from around the...  
  
  Click here to add this to my saved trials
	
									60 Crittenden Blvd # 70
Rochester, New York 14642
	
			Rochester, New York 14642
(585) 275-2121 
							
					Principal Investigator: Johnathan Friedberg, MD
			
						
								
		University of Rochester The University of Rochester is one of the country's top-tier research universities....  
  
  Click here to add this to my saved trials
	
								Houston, Texas 77030			
	
			
					Principal Investigator: Loretta Nastoupil, MD
			
						
										Phone: 832-750-1554
					Click here to add this to my saved trials
	
								New York, New York 10021			
	
			
					Principal Investigator: Peter Martin, MD
			
						
										Phone: 212-746-2190
					Click here to add this to my saved trials
	
								Rochester, Minnesota 55905			
	
			
					Principal Investigator: James Cerhan, MD, PhD
			
						
										Phone: 507-266-2657
					Click here to add this to my saved trials
	
								Saint Louis, Missouri 63110			
	
			
					Principal Investigator: Brad Kahl, MD
			
						
										Phone: 314-747-7638
					Click here to add this to my saved trials